Efficacy and safety of intravitreal aflibercept treat-and-extent for macular edema in central retinal vein occlusion: the centera study

International Journal of Development Research

Volume: 
11
Article ID: 
22236
2 pages
Research Article

Efficacy and safety of intravitreal aflibercept treat-and-extent for macular edema in central retinal vein occlusion: the centera study

Dan Călugăru and Mihai Călugăru

Abstract: 

The authors are commenting on the study entitled: “Efficacy and safety of intravitreal aflibercept treat-and-extend for macular edema in central retinal vein occlusion: Centera study” published in Am J Ophthalmol by Korobelnik 2021; 227(July): 106-115, which assessed the efficacy and safety of intravitreal aflibercept administered using a treat-and-extend dosing regimen in 160 treatment-naïve patients with macular edema secondary to central retinal vein occlusion. The authors concluded that intravitreal aflibercept administered in a treat-and-extend treatment paradigm improved functional and anatomic outcomes in patients with macular edema resulting from central retinal vein occlusion during a 76 week follow-up period. However, the validation, extrapolation, and generalizabilty of these findings can be made only by regression analyses including all the missing data referred to above by us in addition to the baseline characteristics already assessed in this study, serving to identify the potential prognosticators influencing the efficacy and safety of intravitreal aflibercept using a treat-and extend approach for macular edema due to central retinal vein occlusion.

DOI: 
https://doi.org/10.37118/ijdr.22236.07.2021
Download PDF: